A Novel Cardiac Muscle-Derived Biomaterial Reduces Dyskinesia and Postinfarct Left Ventricular Remodeling in a Mouse Model of Myocardial Infarction by O\u27Connor, Daniel M. et al.
Old Dominion University
ODU Digital Commons
Medical Diagnostics & Translational Sciences
Faculty Publications Medical Diagnostics and Translational Sciences
2015
A Novel Cardiac Muscle-Derived Biomaterial
Reduces Dyskinesia and Postinfarct Left







See next page for additional authors
Follow this and additional works at: https://digitalcommons.odu.edu/medicaldiagnostics_fac_pubs
Part of the Physiology Commons
This Article is brought to you for free and open access by the Medical Diagnostics and Translational Sciences at ODU Digital Commons. It has been
accepted for inclusion in Medical Diagnostics & Translational Sciences Faculty Publications by an authorized administrator of ODU Digital Commons.
For more information, please contact digitalcommons@odu.edu.
Repository Citation
O'Connor, Daniel M.; Naresh, Nivedita K.; Piras, Bryan A.; Xu, Yaqin; Smith, Robert S.; and Ogle, Roy C., "A Novel Cardiac Muscle-
Derived Biomaterial Reduces Dyskinesia and Postinfarct Left Ventricular Remodeling in a Mouse Model of Myocardial Infarction"
(2015). Medical Diagnostics & Translational Sciences Faculty Publications. 28.
https://digitalcommons.odu.edu/medicaldiagnostics_fac_pubs/28
Original Publication Citation
O'Connor, D. M., Naresh, N. K., Piras, B. A., Xu, Y. Q., Smith, R. S., Epstein, F. H., . . . French, B. A. (2015). A novel cardiac muscle-
derived biomaterial reduces dyskinesia and postinfarct left ventricular remodeling in a mouse model of myocardial infarction. Physiol
Rep, 3(3), e12351. doi:10.14814/phy2.12351
Authors
Daniel M. O'Connor, Nivedita K. Naresh, Bryan A. Piras, Yaqin Xu, Robert S. Smith, and Roy C. Ogle
This article is available at ODU Digital Commons: https://digitalcommons.odu.edu/medicaldiagnostics_fac_pubs/28
ORIGINAL RESEARCH
A novel cardiac muscle-derived biomaterial reduces
dyskinesia and postinfarct left ventricular remodeling in a
mouse model of myocardial infarction
Daniel M. O’Connor1, Nivedita K. Naresh1, Bryan A. Piras1, Yaqin Xu1, Robert S. Smith1,
Frederick H. Epstein1,2, John A. Hossack1, Roy C. Ogle3 & Brent A. French1,2
1 Department of Biomedical Engineering, University of Virginia, Charlottesville, Virginia
2 Department of Radiology, University of Virginia, Charlottesville, Virginia
3 School of Medical Diagnostic and Translational Sciences, College of Health Sciences, Old Dominion University, Norfolk, Virginia
Keywords
Extracellular matrix, left ventricular
remodeling, myocardial infarction, small
animal imaging, speckle tracking
echocardiography.
Correspondence
Brent A. French, Department of Biomedical
Engineering, University of Virginia Box





This work was supported in part by NIH R01
HL058582 and R01 HL092305 to BAF. The
purchase of the Vevo 2100 was funded by NIH
S10 RR027333 (to JAH) and the 7T MRI system
was funded by NIH S10 RR019911. Additional
funding was provided by a University of
Virginia Harrison Research Award to DMO.
Received: 20 February 2015; Revised: 25
February 2015; Accepted: 4 March 2015
doi: 10.14814/phy2.12351
Physiol Rep, 3(3), 2015, e12351,
doi: 10.14814/phy2.12351
Abstract
Extracellular matrix (ECM) degradation after myocardial infarction (MI)
leaves the myocardium structurally weakened and, as a result, susceptible to
early infarct zone dyskinesia and left ventricular (LV) remodeling. While vari-
ous cellular and biomaterial preparations have been transplanted into the
infarct zone in hopes of improving post-MI LV remodeling, an allogeneic car-
diac muscle-derived ECM extract has yet to be developed and tested in the
setting of reperfused MI. We sought to determine the effects of injecting a
novel cardiac muscle-derived ECM into the infarct zone on early dyskinesia
and LV remodeling in a mouse model of MI. Cardiac muscle ECM was
extracted from frozen mouse heart tissue by a protocol that enriches for base-
ment membrane constituents. The extract was injected into the infarct zone
immediately after ischemia/reperfusion injury (n = 6). Echocardiography was
performed at baseline and at days 2, 7, 14, and 28 post-MI to assess 3D LV
volumes and cardiac function, as compared to infarcted controls (n = 9).
Early infarct zone dyskinesia was measured on day 2 post-MI using a novel
metric, the dyskinesia index. End-systolic volume was significantly reduced in
the ECM-treated group compared to controls by day 14. Ejection fraction and
stroke volume were also significantly improved in the ECM-treated group.
ECM-treated hearts showed a significant (P < 0.005) reduction in dyskinetic
motion on day 2. Thus, using high-frequency ultrasound, it was shown that
treatment with a cardiac-derived ECM preparation reduced early infarct zone
dyskinesia and post-MI LV remodeling in a mouse model of reperfused MI.
Introduction
In its acute stage, myocardial infarction (MI) results in
immediate death to cardiomyocytes and contractile dys-
function. Immune cells infiltrate the area of infarction to
phagocytize necrotic cells and apoptotic cell debris, and
release enzymes that degrade the cardiac extracellular
matrix (ECM) (Dai et al. 2005; French and Kramer 2007;
Jourdan-Lesaux et al. 2010). This causes the infarct zone
to become thinned, structurally weak, and susceptible to
paradoxical bulging under the pressure of systole (early
dyskinesia) (Dai et al. 2005; French and Kramer 2007;
Gersh et al. 2009) prior to scar formation. Early dyskine-
sia not only robs the heart of systolic function, but is also
correlated with maladaptive long-term changes in heart
morphology and function, and thus may contribute
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importantly to left ventricular (LV) remodeling and even-
tual heart failure (French and Kramer 2007).
Although a number of clinical studies have shown that
the transplantation of progenitor or stem cells into the
LV after MI can marginally improve cardiac function, the
data from most such studies fail to show clinically signifi-
cant levels of differentiation (much less survival) of the
transplanted cells (Gersh et al. 2009). These data suggest
that the major benefits of cell transplantation therapy
may not result from replacing lost cardiomyocytes, but
rather from the injected cells serving to reinforce the
infarcted LV walls via a scaffolding effect (Dai et al. 2005)
or by producing cytokines and growth factors that stimu-
late regeneration (Gnecchi et al. 2005).
These current hypotheses surrounding stem cell trans-
plantation therapy support a strategy involving acellular
therapy. ECM components are an attractive material for
acellular therapy because they serve a structural function
and promote cellular adhesion, proliferation, and differ-
entiation (Akhyari et al. 2008). Transplanted ECM
derived from porcine urinary bladders has been found to
become populated with myocytes and improve regional
contractile function in several animal models (Kelly et al.
2009; Singelyn and Christman 2010). ECM composition
is complex, however, and highly variable among species
and cell types and the composition of the extract will
almost certainly determine its properties. Recently, a hy-
drogel derived from porcine cardiac ECM was found to
preserve cardiac function in a rat MI model (Singelyn
et al. 2012).
Matrigel (BD Biosciences, San Jose, CA), a reconstituted
basement membrane-rich extract, has been widely used as a
cell culture substrate for over 30 years (Kleinman et al.
1986). While Matrigel has been implanted to treat postin-
farct myocardium, it is derived from a mouse sarcoma and
is thus comprised of noncardiac matrix components and is
potentially immunogenic outside the mouse, limiting its
clinical potential (Singelyn and Christman 2010). The bio-
chemical protocol used in Matrigel production can be
adapted, however, to other basement membrane-rich tis-
sues such as skeletal muscle (Abberton et al. 2008).
This study sought to determine whether a novel cardiac
muscle-derived ECM extract (“cMatrix”) could improve
cardiac function after reperfused MI. In order to test the
therapeutic potential of cMatrix, high-frequency 3D echo-
cardiography was used to serially assess cardiac function
over 28 days in a mouse model of reperfused MI. Cardiac
magnetic resonance (CMR) was performed in a subset of
mice on day 2 post-MI to determine infarct size, and on
day 28 post-MI to confirm volumetric results. A new met-
ric, here termed the “dyskinesia index” (DI), was developed
to measure early infarct zone dyskinesia, based on wall-
motion data acquired from ultrasound image processing.
Materials and Methods
Experimental design
The experimental design of this study is summarized in
Figure 1. 3D echocardiography was performed at baseline
and on days 2, 7, 14, and 28 post-MI and involved the
capture of a full sweep of short-axis (SA) cines from the
apex to the base of the LV at 1.0 mm intervals. This
imaging was achieved using a custom-built hardware/soft-
ware system that controlled the ultrasound transducer
and triggered the scanner to acquire and store data,
allowing for the full SA stack to be captured in less than
1 min. A novel metric based on the ratio of signed to
unsigned endocardial displacement, here termed the “dys-
kinesia index” (DI), was employed to quantify early
infarct zone dyskinetic motion on post-MI D2. MRI was
performed in a subset of mice on D2 post-MI to deter-
mine infarct size, and on D28 post-MI to confirm volu-
metric results.
Tissue harvesting for cMatrix
This study was conducted under protocols approved by
the University of Virginia Animal Care and Use Commit-
tee. Adult male C57Bl/6 mice purchased from The
Jackson Laboratory (Bar Harbor, ME) were killed with an
overdose of anesthetic and death was confirmed by cervi-
cal dislocation. Hearts were then immediately excised,
rinsed in chilled phosphate-buffered saline (PBS), and
atria were removed. The tissue was then snap-frozen in
liquid nitrogen and stored at 80°C.
cMatrix production
All procedures were performed at 4°C. Frozen mouse tis-
sue was thawed from 70°C in buffered 3.4 M NaCl with
Figure 1. Experimental Design. Fifteen mice received a 1-h
coronary occlusion followed by reperfusion on day 0 (MI). Nine of
these mice were left untreated, while six received cMatrix injection
at reperfusion. All mice were studied using 3D echocardiography,
both at baseline and at 2, 7, 14 and 28 days post-MI. DI analysis
was performed using data collected on day 2 post-MI. MRI scans
were performed in a subset of mice on day 2 post-MI to determine
infarct size, and on day 28 post-MI to confirm volumetric results.
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added protease inhibitors [5 mM ETDA, 2 mM NEM
(Sigma-Aldrich, St. Louis, MO)], in a volume six times
the weight of the sample. The sample was minced into
approximately 1 mm3 pieces using a scalpel and homoge-
nized. The homogenized mixture was then spun at
10,000 9 g for 30 min. The pellet was washed with a
2 M buffered urea solution at a volume equal to the ori-
ginal weight of the tissue. The sample was then stirred
overnight. Next, the sample was centrifuged at
18,000 9 g for 30 min and the supernatant was decanted
and stored at 4°C. Two additional extractions were per-
formed by resuspending and homogenizing the pellet in
urea buffer of one-half the volume of the original tissue
weight, and repeating the centrifugation. Aliquots from
each sample were evaluated for total protein and collagen
content to assess quality. The combined supernatants
were then dialyzed against 0.5% chloroform in tris-buf-
fered saline (TBS) overnight to sterilize the extract. The
extract was further dialyzed twice against TBS to remove
the urea and chloroform, and once against PBS to
enhance physiological compatibility. The final extract was
aliquoted and stored at 20°C.
Protein concentration measurements
Total protein concentration was measured using an assay
kit based on the Lowry method (Bio-Rad, Hercules, CA).
Collagen content was determined using the Sircol soluble
collagen assay kit (Biocolor; Accurate Chemical & Scien-
tific Corporation, Westbury, NY).
Mouse model of reperfused MI
Male C57Bl/6 mice were purchased from Jackson Labora-
tories (Bar Harbor). The mice were between 10–12 weeks
old and weighed 24–29 g at the time of surgery. A stan-
dard myocardial ischemia/reperfusion protocol was
employed, as described previously (Li et al. 2011). Briefly,
the hearts of anesthetized mice were exposed via left tho-
racotomy, and occlusion was induced by passing a suture
around the left anterior descending coronary artery and
tightening it over a piece of polyethylene-60 tubing for
60 min. For the group of mice receiving cMatrix, 15 lL
were injected directly into the anterolateral sector of api-
cal myocardium using a 31-gauge insulin syringe.
Echocardiography
All mice were studied by echocardiography at baseline
and 2, 7, 14, and 28 days after myocardial infarction
(MI). Prior to scanning, fur was shaved from the chest
followed by depilation with Nair cream. Ultrasound B-
mode cardiac image sequences were acquired using a
Vevo 2100 high-resolution ultrasound scanner (Visual-
Sonics Inc., Toronto, ON, Canada). Anesthesia, body
temperature, and EKG monitoring were performed as
described previously (Li et al. 2011).
Six to seven serial parasternal left ventricular (LV)
short-axis (SA) views were captured from the apex to the
base of the LV in 1.0 mm intervals using a custom-built
hardware/software system that controlled the motor stage
holding the transducer and triggered the scanner to
acquire and store image data. This system allowed for the
full SA stack to be captured in less than one minute.
Sequences averaged 30–40 frames per cardiac cycle. The
total ultrasound imaging session duration was under
30 min per mouse.
Left ventricular short-axis cross-sectional areas were
calculated by manually delineating endocardial contours
at end-diastole (ED) and end-systole (ES) at 1 mm inter-
vals from apex to base. ED and ES were determined on a
per slice basis. The LV end-systolic volumes (LVESV) and
LV end-diastolic volumes (LVEDV) were then computed,
and ejection fraction (EF) and stroke volume (SV) were
derived from these values.
The extent of wall thinning was calculated from endo-
cardial and epicardial traces of long-axis images at end-
diastole. Significant wall thinning was defined as a left
ventricular wall thickness of 0.5 mm or thinner, relative
to the normal end-diastolic wall thickness of 1 mm. The
extent was defined as the percentage of the LV wall in
which significant wall thinning occurred.
Echocardiography data analysis
A novel metric, here termed the “dyskinesia index” (DI)
was employed to quantify early infarct zone dyskinetic
motion, based on contraction index, as described by Li
et al. (2011). DI is a measure based on the efficiency (eff)
of endocardial displacement, which is defined as the ratio
of the sum of signed radial displacements to the sum of
unsigned radial displacements for each time point in the
cardiac cycle:
effðtÞ ¼ Ridði; tÞ
Rijdði; tÞj (1)
In this equation, “d” is the mean radial displacement
of each segment “i”, at time point “t”. DI is defined as
the average value of eff(t) over the course of the cardiac






Thus, DI represents the average ratio of the sum of the
signed radial displacements to the sum of the unsigned
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radial displacements, over the cardiac cycle. DI yields
possible values ranging from 0 to 1, where a DI of unity
represents completely polar radial displacement, and
smaller values indicate increasing dyskinetic motion.
In order to measure early infarct zone dyskinetic
motion, DI was calculated on D2 post-MI using a
short-axis slice 2 mm superior to the apex of the LV.
VevoStrain speckle tracking software was used to obtain
endocardial radial displacements for 96 segments over the
course of a cardiac cycle (VisualSonics Inc.) and DI was
calculated as defined by Equation 2.
MRI
MRI was performed in a subset of mice on D2 post-MI
to determine infarct size, and on D28 post-MI to confirm
volumetric results using previously described methods on
a 7T MRI scanner (Bruker, Ettlingen, Germany) (Helm
et al. 2008). Infarct sizes were determined in cMatrix-
treated (n = 3) and infarcted control (n = 6) mice on day
2 post-MI using late gadolinium-enhanced (LGE) CMR
images. Infarct size was expressed as a percentage of the
total LV mass. Post-MI day 28 volumetrics were deter-
mined for 3 cMatrix-treated mice using a black blood
gradient echo pulse sequence imaging as described
previously (Helm et al. 2008). A set of six to eight contig-
uous SA cine images were then acquired to cover the
entire LV.
Tissue harvesting and histology
At D29 post-MI, the mice were killed with an overdose of
anesthetic, and death was confirmed by cervical disloca-
tion. Hearts were immediately excised and washed in
PBS. The apical half of each heart was fixed in parafor-
maldehyde overnight at 4°C. The tissue was then washed
three times in PBS and stored in 70% ethanol prior to
embedding in paraffin and sectioning (5 lm thickness).
Tissue sections were then stained with picrosirius red to
detect collagen.
Statistical analysis
All data are presented as mean  SEM. Statistical signifi-
cance was presumed where P < 0.05. Data collected dur-
ing reperfusion (days 2–28) were analyzed using two-way
ANOVA for repeated measures. Post hoc analyses (Bon-
ferroni post tests) were performed where appropriate. All
other statistical analysis was performed using a two-tailed,
unpaired Student’s t-test. Statistical analyses were




Using the Lowry total protein assay, cMatrix had a total
protein concentration of 5.1 mg/mL. Concentration of
collagen types I through V was 240 mg per mg of total
protein. Both the total protein and collagen concentration
of cMatrix are comparable to the levels reported in simi-
lar extracts, such as Myogel and Matrigel (Kleinman et al.
1986; Abberton et al. 2008). The composition of cMatrix
is likely most similar to that of the skeletal muscle-
derived Myogel, which contains a mixture of predomi-
nately Type I and Type IV collagens, in addition to lami-
nins, proteoglycans, and growth factors.
LV remodeling and cardiac function
The LV remodeling study included 9 control and 6 cMa-
trix-treated mice subjected to 60 min of ischemia fol-
lowed by reperfusion. Mortality during surgery and over
the course of the imaging period was similar in control
and cMatrix-treated groups: one mouse from the control
group died on day 3 post-MI after a poor recovery from
surgery, and a cMatrix-treated mouse had to be killed
during the last week of the study due to inadvertent
injury. Volumetric data are reported relative to the base-
line LV volumes for each group due to a small, but statis-
tically significant, difference in baseline LV end-diastolic
volume (LVEDV) between groups.
Serial 3D echocardiography performed at baseline and
on days 2, 7, 14, and 28 post-MI showed improved LV
remodeling and cardiac function in cMatrix-treated mice
(Fig. 2). Late-gadolinium-enhanced (LGE) CMR imaging
performed on day 2 confirmed no significant difference
in acute infarct size as a percent of LV mass between
groups (controls = 31.4  1.3% of LV, cMatrix-
treated = 35.4  6.8% of LV; P = NS). Relative LV end-
systolic volume (LVESV) was found to be significantly
reduced in cMatrix-treated mice by day 14 and remained
significant (P < 0.05) at day 28 (Fig. 2A; results expressed
as fold changes relative to baseline). On day 28, the cMa-
trix-treated mice showed a 28% improvement in relative
LVESV compared to the control group. While there was
no significant difference in LVEDV between groups
(Fig. 2B), LV ejection fraction (EF) was also found to be
significantly improved in cMatrix versus control mice by
day 14 and remained improved through day 28 (Fig. 2C;
P < 0.05 at both time points). On day 28, EF was
35.0  3.0% in cMatrix-treated mice versus 27.1  2.0%
in controls. By day 28, relative stroke volume (SV) was
22% greater in cMatrix vs. control mice (Fig. 2D;
2015 | Vol. 3 | Iss. 3 | e12351
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P < 0.05). A CMR follow-up study was performed to
confirm these results in a subset of animals on day 28
(n = 3). No statistically significant differences in LVESV
or LVEDV were found between the two modalities.
Early infarct zone dyskinetic wall motion
To determine the effect of cMatrix on early infarct dyskine-
sia, displacement data were obtained from speckle tracking
analysis of echocardiographic image series collected on day
2 post-MI from short-axis (SA) image planes positioned
2 mm superior to the apex of the heart. Figure 3A shows a
short-axis image of an uninfarcted heart in systole, with
arrows representing displacement vectors. A post-MI day 2
animal with severe paradoxical systolic bulging in the ante-
rior and anterolateral segments of myocardium is shown in
Figure 3B, with the area of dyskinetic motion highlighted
in the white box, and in Figure 3C. Figure 3D shows a map
defining the locations of the endocardial radial displace-
ments that were determined over the course of a complete
heart cycle. Figure 3E–G show graphs with the SA linear-
ized along the y-axis, allowing displacement data (z-axis)
over the course of the cardiac cycle (x-axis) to be viewed
for each SA segment in an uninfarcted mouse (Fig. 3E), an
untreated control mouse on day 2 post-MI (Fig. 3F), and a
day 2 post-MI cMatrix mouse (Fig. 3G). Note that
although both MI groups show deficits in contractile func-
tion in the anterolateral wall, the cMatrix group is pro-
tected from regional bulging (orange box). These findings
were quantified using the novel DI metric, which was found
to be significantly improved in cMatrix-treated (91.2 
2.2%) versus untreated hearts (71  5.2%; Fig. 3H,
P < 0.005).
Histological confirmation of cMatrix
injection and reinforcement of the LV
The presence of cMatrix in the LV was confirmed by observ-
ing a thickening of the anterior septum surrounding the site
of injection using CMR imaging on day 28 (Fig. 4A) and by
histological analysis (Fig. 4B). Picrosirius red staining
revealed a significant collagen deposit reinforcing the antero-
septal wall. Figure 4C demonstrates the border (dashed line)
between native collagen tissue deposition (right) and the
relatively denser-staining, and less cellular injected matrix.
The extent of wall thinning, measured by ultrasound as the
percentage of long-axis tissue with a thickness of less than
0.5 mm on ultrasound, was significantly decreased in the
cMatrix-treated group as early as post-MI day 2 (Fig. 4D).
This decrease was preserved on day 28 (P < 0.05).
A B
C D
Figure 2. cMatrix treatment helps to preserve cardiac function and inhibits post-MI LV remodeling. (A) Relative LVESV was significantly
reduced in the cMatrix-treated group (n = 6), compared to controls (n = 9) by day 14 post-MI. (B) Relative LVEDV was reduced at each time
point measured over 28 days post-MI, although this trend failed to achieve statistical significance. (C) EF in the cMatrix group was significantly
improved over the untreated group at days 14 and 28 post-MI. (D) By day 28, SV was significantly improved in the cMatrix-treated group.
*P < 0.05 vs. untreated, infarcted control group at the same time point.
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Figure 3. cMatrix treatment reduces early infarct zone dyskinetic wall motion. (A) A short-axis image of an uninfarcted heart in systole, with
arrows representing displacement vectors. (B) A post-MI day 2 animal with severe paradoxical systolic bulging in the anterior and anterolateral
segments of myocardium (white box), highlighted in “C”. (D) Standard six-sector LV short-axis (SA) segmentations are overlaid on a B-mode
echocardiographic image taken 2 mm superior to the apex. “A,” anterior; “AL,” anterolateral; “AS,” anterior septum; “P,” posterior; “PL,”
posterolateral; “PS,” posterior septum. “E–G” are three-dimensional representations of SA endocardial radial displacements over the course of
a complete heart cycle in (E) normal, (F) day 2 post-MI untreated, and (G) day 2 post-MI cMatrix-treated mouse hearts. Dark blue regions
indicate dyskinetic displacements as highlighted by the orange box. (H) cMatrix-treated hearts (n = 6) showed a significant improvement in
dyskinesia index (DI) on day 2 post-MI compared to untreated controls (n = 9). A DI of unity represents completely polar radial displacement,
whereas smaller values indicate increasing dyskinetic motion (*P < 0.005 vs. infarcted control).
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Discussion
This study describes the preparation and evaluation of
cMatrix, a novel cardiac muscle-derived biomaterial. After
reperfused MI, cMatrix-treated mice were shown to have
reduced LV remodeling compared to infarcted control
mice. Furthermore, speckle tracking displacement data
were used to show that cMatrix reduced early infarct zone
dyskinesia, as quantified using the novel dyskinesia index
(DI).
The cMatrix extract provides a number of advantages
over previously tested scaffolds. Unlike solid scaffolds or
patches, liquid scaffolds are not limited to superficial
placement on the epicardial surface of the heart and have
the ability to fully adapt to their environment (Singelyn
and Christman 2010).
Furthermore, because they can be implanted via percuta-
neous trans-coronary-venous or transendocardial injection,
liquid scaffolds have greater clinical potential than patches,
which can only be implanted surgically (Singelyn and
Christman 2010). As cMatrix is an acellular therapy, it
avoids risks of aberrant cellular differentiation and inadver-
tent cell seeding in off-target organs, as well as the potential
ethical concerns associated with embryonic stem cells.
Because cMatrix is a naturally derived material, all its
components are biocompatible and can be safely degraded
or renewed in vivo. Additionally, synthetic compounds
lack the rich combination of proteins, polysaccharides,
and other ECM components that exist in a direct cardiac
tissue extract such as cMatrix. Finally, cMatrix is directly
derived from cardiac tissue, and therefore provides the
closest possible approximation of the native cardiac envi-
ronment critical to both safety and efficacy. A human-
derived version of cMatrix could be produced with mini-
mal manipulation and might well meet the FDA criteria
for a Human Cell and Tissue Product (HCT/P), thus
finding its way to the bedside more rapidly than many
medical devices or drugs.
A potential limitation of this study is the use of
untreated, infarcted mice as the negative controls, as
A B
C D
Figure 4. Confirmation of cMatrix injection and reinforcement of the LV. (A) An in vivo MRI short-axis (SA) image of a day 28 post-MI heart
treated with cMatrix. (B) A histological slice of the boxed region (anterior septum) taken from the same animal shown in “A”. The tissue slice
was stained with picrosirius red, which colors collagen red and other tissue yellow. Scale Bar = 250 lm. (C) Picrosirius red stained tissue from
the apical anterior wall of a cMatrix-treated mouse. The dashed line delineates the border between native tissue (right) and the relatively
denser-staining, and less cellular injected matrix. The star denotes the ventricular chamber. Scale Bar = 100 lm. (D) The extent of wall thinning,
measured by ultrasound as the percentage of long-axis tissue with a thickness of less than 0.5 mm, was significantly decreased in the cMatrix-
treated group as early as post-MI day 2. This decrease was preserved through day 28 (*P < 0.05).
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opposed to infarcted mice injected with an equal volume
of vehicle. However, we elected to use untreated, infarcted
animals to better approximate the clinical situation in
which patients either would receive treatment or would
be left untreated. Furthermore, trauma from the needle
and injected fluid might worsen cardiac function in such
a vehicle control group, thus potentially overestimating
the efficacy of cMatrix treatment relative to uninjected
controls. A second potential limitation of this study is
that it did not directly compare the injection of cMatrix
to Matrigel or an alternative mixture of ECM proteins.
While such alternative tissue extracts or ECM mixtures
might well be successful in attenuating LV remodeling
(Dai et al. 2005; Singelyn et al. 2012), one can predict
that the power of such a comparative study would have
to be much greater, involving many more animals, in
order to capture a statistical difference between two or
more materials.
The cardiac matrix preparation is a complex solution
containing ECM and cardiac muscle—in essence a lique-
fied tissue product. Some elements of the extract promote
cardiac regeneration and others appear to serve as a bio-
compatible delivery vehicle. Although it is of scientific
importance to identify and understand which key compo-
nents of the extract support regenerative activity, there is
also value inherent in the simplicity of this biomaterial.
The Food and Drug Administration employs the concept
of minimal manipulation in classifying therapeutic agents
produced from cells and tissues. The cardiac matrix
described here is minimally manipulated and, arguably,
could be available for clinical use as a human or cell
product far sooner than a purified, manufactured product
representing only the “active” ingredients in an approved
carrier/delivery system. In the latter case, as a medical
device or PMA, the FDA would require clinical trials,
adding significantly to the time to bring the potential
therapy to the patient.
Early dyskinesia after MI has previously been shown to
contribute to LV remodeling (French and Kramer 2007).
Indeed, our laboratory has previously demonstrated that
the extent of this early paradoxical wall motion is an
extremely strong predictor of subsequent LV remodeling
(Li et al. 2011). This relationship may be the result of
repeated cycles of systolic bulging and abnormal loading
conditions causing infarct expansion and leading to posi-
tive feedback between LV remodeling and cardiac dys-
function in the subacute period prior to the formation of
mature scar (Mann and Bristow 2005; French and Kramer
2007). In this study, we demonstrate that injection of
cMatrix reduced early infarct zone dyskinesia independent
of infarct size and attenuated LV remodeling, compared
to infarcted controls. This effect could be seen as early as
post-MI day 2, prior to the development of significant
differences in systolic function and chamber sizes. This
time point is prior to the onset of significant infarct
expansion, scar formation, and other regenerative pro-
cesses, such as neovascularization. It is therefore likely
that cMatrix reduced LV remodeling at least partially
through this direct mechanical mechanism.
The importance of early reinforcement could be fur-
ther tested by assessing LV remodeling after delivering
cMatrix at later time points post-MI. If early reinforce-
ment is critical to the inhibition of LV remodeling, it is
conceivable that targeting genes that control early ECM
degradation (e.g., MMPs or TIMPs) may also have ther-
apeutic effects on LV remodeling. This strategy would
become particularly attractive with the advent of new
gene delivery systems that rapidly and selectively target
the infarct border zone after reperfused MI (Konkalmatt
et al. 2012).
The nonstructural effects of cMatrix on LV remodeling
remain to be examined, but are likely to be highly com-
plex, in part because ECM composition over the course
of LV remodeling is a dynamic and delicate balance of
degradation and synthesis (French and Kramer 2007;
Akhyari et al. 2008). In addition, various components of
the ECM may have different effects on LV remodeling
depending on their relative abundance and surrounding
environment. For example, fibronectin fragments stimu-
late ECM degradation, but have also been shown to
prevent apoptosis in injured cardiomyocytes (Arslan et al.
2011). Furthermore, extracts rich in basement membrane,
such as cMatrix, have been shown to promote angiogene-
sis (Kleinman and Martin 2005). While the primary focus
of this study was on the early mechanical effects of the
cMatrix injection, a more detailed analysis of the effect of
cMatrix on endogenous ECM synthesis and degradation
post-MI could potentially shed light on additional mecha-
nisms behind the treatment’s effects on remodeling.
Much of the complex role of ECM in LV remodeling
remains to be defined. Analysis and selective modification
of cMatrix content may yield insight into the factors and
mechanisms contributing to cardiac regeneration, paving
the way for other novel strategies for curtailing LV
remodeling post-MI.
Acknowledgments
The authors wish to thank Donald Aduba Jr for his
guidance developing the cMatrix purification protocol.




2015 | Vol. 3 | Iss. 3 | e12351
Page 8
ª 2015 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
Biomaterial Protects Against LV Remodeling D. M. O’Connor et al.
References
Abberton, K. M., S. K. Bortolotto, A. A. Woods, M. Findlay,
W. A. Morrison, E. W. Thompson, et al. 2008. Myogel, a
novel, basement membrane-rich, extracellular matrix derived
from skeletal muscle, is highly adipogenic in vivo and
in vitro. Cells Tissues Organs 188:347–358.
Akhyari, P., H. Kamiya, A. Haverich, M. Karck, and A.
Lichtenberg. 2008. Myocardial tissue engineering: the
extracellular matrix. Eur. J. Cardiothorac. Surg. 34:
229–241.
Arslan, F., M. B. Smeets, P. W. Riem Vis, J. C. Karper, P. H.
Quax, L. G. Bongartz, et al. 2011. Lack of fibronectin-EDA
promotes survival and prevents adverse remodeling and
heart function deterioration after myocardial infarction.
Circ. Res. 108:582–592.
Dai, W., L. E. Wold, J. S. Dow, and R. A. Kloner. 2005.
Thickening of the infarcted wall by collagen injection
improves left ventricular function in rats: a novel approach
to preserve cardiac function after myocardial infarction. J.
Am. Coll. Cardiol. 46:714–719.
French, B. A., and C. M. Kramer. 2007. Mechanisms of post-
infarct left ventricular remodeling. Drug Discov. Today Dis.
Mech. 4:185–196.
Gersh, B. J., R. D. Simari, A. Behfar, C. M. Terzic, and A.
Terzic. 2009. Cardiac cell repair therapy: a clinical
perspective. Mayo Clin. Proc. 84:876–892.
Gnecchi, M., H. He, O. D. Liang, L. G. Melo, F. Morello, H.
Mu, et al. 2005. Paracrine action accounts for marked
protection of ischemic heart by Akt-modified mesenchymal
stem cells. Nat. Med. 11:367–368.
Helm, P. A., P. Caravan, B. A. French, V. Jacques, L. Shen, Y.
Xu, et al. 2008. Postinfarction myocardial scarring in mice:
molecular MR imaging with use of a collagen-targeting
contrast agent. Radiology 247:788–796.
Jourdan-Lesaux, C., J. Zhang, and M. L. Lindsey. 2010.
Extracellular matrix roles during cardiac repair. Life Sci.
87:391–400.
Kelly, D. J., A. B. Rosen, A. J. T. Schuldt, P. V. Kochupura, S.
V. Doronin, I. A. Potapova, et al. 2009. Increased myocyte
content and mechanical function within a tissue-engineered
myocardial patch following implantation. Tissue Eng. Part A
15:2189–2201.
Kleinman, H. K., and G. R. Martin. 2005. Matrigel: basement
membrane matrix with biological activity. Semin. Cancer
Biol. 15:378–386.
Kleinman, H. K., M. L. McGarvey, J. R. Hassell, V. L. Star, F.
B. Cannon, G. W. Laurie, et al. 1986. Basement membrane
complexes with biological activity. Biochemistry 25:312–318.
Konkalmatt, P. R., F. Wang, B. A. Piras, Y. Xu, D. M.
O’Connor, R. J. Beyers, et al. 2012. Adeno-associated virus
serotype 9 administered systemically after reperfusion
preferentially targets cardiomyocytes in the infarct
border zone with pharmacodynamics suitable for the
attenuation of left ventricular remodeling. J. Gene Med.
14:609–620.
Li, Y., C. D. Garson, Y. Xu, P. A. Helm, J. A. Hossack, and B.
A. French. 2011. Serial ultrasound evaluation of
intramyocardial strain after reperfused myocardial infarction
reveals that remote zone dyssynchrony develops in concert
with left ventricular remodeling. Ultrasound Med. Biol.
37:1073–1086.
Mann, D. L., and M. R. Bristow. 2005. Mechanisms and
models in heart failure: the biomechanical model and
beyond. Circulation 111:2837–2849.
Singelyn, J. M., and K. L. Christman. 2010. Injectable materials
for the treatment of myocardial infarction and heart failure:
the promise of decellularized matrices. J. Cardiovasc. Transl.
Res. 3:478–486.
Singelyn, J. M., P. Sundaramurthy, T. D. Johnson, P. J. Schup-
Magoffin, D. P. Hu, D. M. Faulk, et al. 2012. Catheter-
deliverable hydrogel derived from decellularized ventricular
extracellular matrix increases endogenous cardiomyocytes
and preserves cardiac function post-myocardial infarction. J.
Am. Coll. Cardiol. 59:751–763.
ª 2015 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
2015 | Vol. 3 | Iss. 3 | e12351
Page 9
D. M. O’Connor et al. Biomaterial Protects Against LV Remodeling
